Actinogen Medical Ltd (ASX: ACW) Alzheimer’s Treatment Receives Final Market Patent

KEY TAKEAWAYS:

• The Canadian Intellectual Property Office approved another major patent for Xanamem, Actinogen Medical Limited (ASX: ACW) breakthrough Alzheimer’s treatment
• Xanamem now holds a patent in over 80% of Alzheimer’s market worldwide including Japan, European Union, United Kingdom, China, United States and Australia

Actinogen Medical Limited (ASX: ACW) announced that the Canadian Intellectual Property Office has approved a patent for Xanamem in Canada for a period up to 2031. This means Xanamem now has patents in all major markets in the world including Japan, European Union, United Kingdom, China, United States and Australia. These countries represent more than 80% of Alzheimer’s market worldwide.

Xanamem, which was discovered by Dr Scott Webster and Professor Brian Walker, was developed as a treatment for Alzheimer’s diseases. Scientists believe that increased cortisol levels in the blood lead to the disease. Xanamem aims to reduce the harmful effects of the disease by blocking the production of cortisol.

The hypothesis that increased cortisol levels cause Alzheimer’s disease is supported by the Australian Imaging, Biomarker & Lifestyle Study of Ageing (AIBL) study. The authors agreed that Alzheimer’s diseases could be prevented by lowering the levels of cortisol.

The patent for Xanamem, however, covers not only Alzheimer’s diseases but a wide array of metabolic and neurological diseases. It also includes a patent for Xanamem’s composition. Those in the pharmaceutical industry usually seek patents for compositions and compounds as well as exclusive rights to the concerned drugs and this is the patent awarded to Xanamem.

“The strength of the Xanamem IP we are developing is reaffirmed with the grant of patents in these key countries. Xanamem is now patent protected in more than 80% of the global Alzheimer’s market, signalling the significant value of the Xanamem IP that we hope to commercialise in the future.” Actinogen Medical CEO and Managing Director Dr Bill Ketelbey said.

Actinogen Limited, now known as Ectinogen Medical Limited, specialises in the treatment of mild cognitive impairment and the more serious dementia and Alzheimer’s disease. The company is developing Xanamem, a drug that aims to treat not only Alzheimer’s but also neurodegenerative diseases related to age.

Request Information